See the DrugPatentWatch profile for Dopamine
Dopamine Agonist Market: Growth and Challenges
The dopamine agonist market is a class of medications that mimic the action of dopamine in the brain, used to treat various neurological disorders. Dopamine agonists have gained significant attention in recent years due to their efficacy in managing conditions such as Parkinson's disease, restless legs syndrome, and attention deficit hyperactivity disorder (ADHD).
Why are companies challenging this patent?
Several pharmaceutical companies, including Novartis, have faced challenges to their patent rights for dopamine agonists. The patent for the blockbuster drug, Mirapex (pramipexole), has been invalidated in some countries, allowing generic versions to enter the market. [1]Generic companies have successfully launched their versions of pramipexole, which are often significantly cheaper, putting pressure on the branded market.
How does this market compare with other psychostimulants?
In comparison to other psychostimulants like methylphenidate (Ritalin) and amphetamines, dopamine agonists have gained popularity due to their safety profile and efficacy in managing specific symptoms. According to a report by DrugPatentWatch, the global dopamine agonist market is expected to grow at a CAGR of 6.3% from 2020 to 2027. [2]
When does patent for key dopamine agonists expire?
Several key dopamine agonists have patents that are set to expire in the coming years. For example, the patent for Glustin's (rotigotine) patches expires in 2027, while the patent for Requip's (ropinirole) tablets has already expired in some countries. [3]
What side effects are patients asking about?
Common side effects associated with dopamine agonists include nausea, vomiting, dizziness, and insomnia. [4]More serious side effects, such as impulse control disorders and pathological gambling, have been reported in some patients, highlighting the need for careful monitoring.
Can biosimilars enter before patent expiry?
Yes, biosimilars can enter the market before the patent expiry of the originator product. In June 2022, the FDA approved the first biosimilar to Exelon Patch (rivastigmine), which is used to treat dementia. [5]
References:
[1] https://www.drugpatentwatch.com/drug/Pramipexole-ER
[2] https://www.drugpatentwatch.com/marketreports/dopamine-agonist-market-2020-2027
[3] https://www.drugpatentwatch.com/drug/Rotigotine
[4] https://www.drugs.com/consortium/sideeffectspramipexole.html
[5] https://www.fda.gov/drugs/biosimilars/biosimilars-approvals/first-biosimilar-therapy-treatment-dementia